Moleculin Biotech, Inc. financial data

Symbol
MBRX on Nasdaq
Industry
Pharmaceutical Preparations
Location
5300 Memorial Drive, Suite 950, Houston, TX
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 396 % -48.1%
Debt-to-equity 33.5 % +170%
Return On Equity -100 % -68.2%
Return On Assets -75 % -41.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.56M shares -91.4%
Common Stock, Shares, Outstanding 2.56M shares -91.4%
Entity Public Float 16M USD -60%
Common Stock, Value, Issued 3K USD -90%
Weighted Average Number of Shares Outstanding, Basic 2.54M shares +28.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 18.3M USD -7.43%
General and Administrative Expense 9.35M USD -15.5%
Operating Income (Loss) -27.7M USD +10.3%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -25.2M USD +14%
Earnings Per Share, Basic -11.6 USD/shares +46.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10.8M USD -66.3%
Assets, Current 13.7M USD -61.2%
Property, Plant and Equipment, Net 221K USD -3.49%
Operating Lease, Right-of-Use Asset 475K USD +32.7%
Assets 25.6M USD -45.7%
Accounts Payable, Current 2.83M USD -31.5%
Employee-related Liabilities, Current 1.16M USD
Accrued Liabilities, Current 2.91M USD +20.5%
Liabilities, Current 5.75M USD -12.3%
Operating Lease, Liability, Noncurrent 420K USD +44.3%
Liabilities 7.87M USD +14.9%
Retained Earnings (Accumulated Deficit) -141M USD -21.7%
Stockholders' Equity Attributable to Parent 17.7M USD -56%
Liabilities and Equity 25.6M USD -45.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.72M USD -11.6%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 2.56M shares -91.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.73M USD -14.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 10.8M USD -66.3%
Deferred Tax Assets, Valuation Allowance 32.3M USD +25.7%
Deferred Tax Assets, Gross 32.4M USD +25.7%
Operating Lease, Liability 574K USD +27.3%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -25.2M USD +14%
Lessee, Operating Lease, Liability, to be Paid 712K USD +29.5%
Operating Lease, Liability, Current 112K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 159K USD +45.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 146K USD -4.58%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 138K USD +39.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 164K USD +60.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 339K USD +43.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 141K USD +34.3%
Operating Lease, Payments 125K USD -7.41%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 129K USD +3.2%
Deferred Tax Assets, Net of Valuation Allowance 112K USD +30.2%
Share-based Payment Arrangement, Expense 1.92M USD -14.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%